

AKUMS
DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

Ref: Akums/Exchange/2026-27/10

May 14, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Press Release

Respected Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend

New Delhi, May 2026: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company delivered a steady performance during Q4 FY26, with healthy revenue growth and improved operating profitability driven by its core domestic CDMO business.

For Q4 FY26, Akums reported an operating revenue of ₹1,158 crore, reflecting a 9.7% year-on-year growth compared to ₹1,056 crore in Q4 FY25. Adj EBITDA stood at ₹152 crore, registering a 61.6% year-on-year increase from ₹94 crore in the same quarter last year. Adj EBITDA margin improved to 13.1% from 8.9%. Adj PAT stood at ₹83 crore, compared to ₹35 crore in Q4 FY25, reflecting a 135% year-on-year growth, with Adj PAT margin improving to 7.0% from 3.3%.

On a full-year basis, FY26 operating revenue stood at ₹4,359 crore, growing 5.9% year-on-year over ₹4,118 crore in FY25. Adj EBITDA increased 13.3% year-on-year to ₹522 crore, while Adj PAT grew 27.3% year-on-year to ₹276 crore.

The CDMO segment was the key growth driver for Akums during Q4FY26. CDMO revenue grew to ₹952 crore, compared to ₹840 crore in Q4 FY25. CDMO EBITDA increased 54.9% year-on-year to ₹137 crore, while EBITDA margin improved to 14.4% from 10.6%. This performance was driven by continued customer engagement, better capacity utilisation and focused execution.

The Domestic Branded Formulations business remained stable during the quarter, with Q4 FY26 revenue at ₹102 crore compared to ₹104 crore in Q4 FY25. EBITDA remained steady at ₹22 crore. For the full year, the segment showed improved profitability, with revenue growing 2.9% year-on-year to ₹446 crore and EBITDA increasing 17.0% to ₹90 crore.

The International Branded Formulation business saw some moderation in quarterly revenue, with Q4 FY26 revenue at ₹36 crore compared to ₹40 crore in Q4 FY25. For FY26, revenue remained flat at ₹143 crore, though EBITDA increased 32.3% year-on-year to ₹36 crore.

Trade generics turned a corner with EBITDA becoming positive at Rs 1.4 crore in Q4 FY 26. For FY26, EBITDA loss decreased sharply to Rs 10 crore from Rs 28 crore in FY25.

During FY26, Akums achieved significant progress towards becoming a global pharmaceutical company. The company made its first commercial supply of formulations to Europe, strengthened its regulated market presence with EU GMP certifications for its Oral Solids and Oral Liquids facilities, and received its first UK MHRA approval for Rivaroxaban. Akums injectable plant also received Brazil ANVISA. The ground-breaking of the Zambia pharmaceutical plant marked an important milestone in the company's international journey.

The Board also recommended final dividend for the year FY25-26 of INR 1 per equity share (50% of the face value of INR 2) and a special dividend of INR 2 per equity share (100% of the face value of INR 2).

Commenting on the performance, Mr. Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said: “FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients.”

Mr. Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., added: “The Q4FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitization and automation initiatives which will deliver long-term value for the organization.”

While the overall performance remained positive, the API business continued to face pricing pressure. During Q4 FY26, API revenue was ₹41 crore compared to ₹50 crore in Q4 FY25, with an operating loss of 12 crore. On a full-year basis, API revenue was lower year-on-year, though the EBITDA loss marginally reduced from ₹44 crore in FY25 to ₹40 crore in FY26. The company continues to focus on portfolio optimization, cost control and operational efficiency to support sustainable growth going forward.

Results are as under:

Particulars (Rs Cr)	Q4 FY 26	Q3 FY 26	Q4 FY 25	FY 26	FY 25
Revenue	1,158	1,160	1,056	4,359	4,118
Cost of goods sold	660	679	639	2,514	2,433
Employee Cost	199	189	184	754	716
Other Expenses	147	145	139	570	508
Adj EBITDA	152	147	94	522	461
Adj EBITDA Margin	13.1%	12.7%	8.9%	12.0%	11.2%
Adj PAT	83	86	35	276	217
Adj PAT Margin	7.0%	7.2%	3.3%	6.2%	5.2%

Definitions

- Adj EBITDA: Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization + exceptional items – other income
- Adj PAT: PAT + Fair value changes to financial instrument + Exceptional items – one-time impact of deferred tax in FY 25 of INR 106 cr
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients

For further information, please contact:

IR Desk

Akums Drugs and Pharmaceuticals Ltd

investors@akums.net/ankit.jain@akums.net